Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination

Infection and Immunity

Volumn 70, Issue 1, 2002, Pages 62-68

  Papadopoulou, B ^a   Roy, G ^a   Breton, M ^a   Kundig C ^a   Dumas, C ^a   Fillion, I ^a   Singh, A K ^a   Olivier, M ^a   Ouellette, M ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPTERIN; CARRIER PROTEIN; GAMMA INTERFERON; MUTANT PROTEIN; PTERIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL GROWTH; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DISRUPTION; GENETIC RECOMBINATION; IMMUNITY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ISOLATION; SPLEEN CELL; VACCINATION;

ANIMALS; BIOLOGICAL TRANSPORT; BIOPTERIN; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; GENE TARGETING; INTERFERON TYPE II; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED BALB C; MUTAGENESIS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 0036137174     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.1.62-68.2002     Document Type: Article

References (45)

1. Subunit vaccination of mice against New World cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants
2. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response
3. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
4. The role of nitric oxide in innate immunity
5. Cultivation and in vitro cloning or procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Short communication
6. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi
7. Plasticity in chromosome number and testing of essential genes in Leishmania by targeting
8. Regulation of differentiation to the infective stage of the protozoan parasite Leishmania major by tetrahydrobiopterin
9. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis
10. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages
11. Metabolism and functions of trypanothione in the Kinetoplastida
12. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection
13. Selection against the dihydrofolate reductase-thymidylate synthase (DHFR-TS) locus as a probe of genetic alterations in Leishmania major
14. Leishmaniasis: Current status of vaccine development
15. Leishmaniasis
16. Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite
17. Cytokine-producing T cell subsets in human leishmaniasis
18. Leishmania-specific T cells expressing interferongamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis
19. Splenic cytokine responses in Indian kala-azar before and after treatment
20. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan
21. The growth and nutrition of Crithidia fasciculata
22. Increased transport of pteridines compensates for mutations in the high affinity folate transporter and contributes to methotrexate resistance in the protozoan parasite Leishmania tarentolae
23. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice
24. The leishmania donovani LD1 locus gene ORFG encodes a biopterin transporter (BT1)
25. Gene disruptions indicate an essential function for the LmmCRK1 cdc2- related kinase of Leishmania mexicana
26. Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene
27. An amplified DNA element in Leishmania encodes potential integral membrane and nucleotide-binding proteins
28. New approaches to Leishmania chemotherapy: Pteridine reductase 1 (PTR1) as a target and modulator of antifolate sensitivity
29. Importance of lymphokines in the control of multiplication and dispersion of Leishmania donovani within liver macrophages of resistant and susceptible mice
30. Antifolate resistance mechanisms from bacteria to cancer cells with emphasis on parasites
31. Recent progress in vaccine development against Leishmania species infections
32. Autonomous replication of bacterial DNA plasmid oligomers in Leishmania
33. A novel antifolate resistance gene on the amplified H circle of Leishmania
34. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models
35. Adaptation of leishmania cells to in vitro culture results in a more efficient reduction and transport of biopterin
36. LD1 amplifications in Leishmania
37. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening
38. The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes
39. Experimental visceral leishmaniasis: Role of endogenous IFN-gamma in host defense and tissue granulomatous response
40. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis
41. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the Indian epidemic
42. Development of a safe live Leishmania vaccine line by gene replacement
43. Pteridine requirement of the hemoflagellate Leishmania tarentolae
44. Loss of virulence in Leishmania donovani deficient in an amastigote-specific protein, A2